Screener
Allogene Therapeutics ALLO Retained Earnings
Retained Earnings at other companies
Other financials
Where this comes from
Reported directly by Allogene Therapeutics in its filing.
Tagged under the XBRL concept us-gaap:RetainedEarningsAccumulatedDeficit.
The source filing: Allogene Therapeutics’s 10-Q, filed May 13, 2026.
- Filed
- May 13, 2026, 4:05 PM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001628280-26-034585
| Line item | March 31,2026 | December 31,2025 |
|---|---|---|
| Stockholders’ equity: | ||
| Preferred stock, $0.001 par value: 10,000,000 shares authorized as of March 31, 2026 and December 31, 2025; no shares were issued and outstanding as of March 31, 2026 and December 31, 2025 | — | — |
| Common stock, $0.001 par value: 400,000,000 shares authorized as of March 31, 2026 and December 31, 2025; 244,816,413 and 229,413,523 shares issued and outstanding as of March 31, 2026 and December 31, 2025, respectively | 245 | 229 |
| Additional paid-in capital | 2,332,129 | 2,302,753 |
| Accumulated deficit | (2,053,316) | (2,010,709) |
| Accumulated other comprehensive income (loss) | (183) | 269 |
| Total stockholders’ equity | 278,875 | 292,542 |
| Total liabilities and stockholders’ equity | $395,958 | $415,905 |
Item 1. Financial Statements - Unaudited
FAQ
- What is Allogene Therapeutics's retained earnings?
- Allogene Therapeutics (ALLO) reported retained earnings of -$2.05B in Q1 2026.
- How has Allogene Therapeutics's retained earnings changed year-over-year?
- Allogene Therapeutics's retained earnings decreased by 9.2% year-over-year, from -$1.88B to -$2.05B.
- What is the long-term trend for Allogene Therapeutics's retained earnings?
- Over 5 years (2020 to 2025), Allogene Therapeutics's retained earnings has grown at a 23.1% compound annual growth rate (CAGR), from -$712.5M to -$2.01B.
- What does retained earnings mean?
- Cumulative net income earned since inception minus all dividends paid — the total profits reinvested in the business over its lifetime.
Ask your AI about Allogene Therapeutics's retained earnings.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude